Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026)
Avalo Therapeutics' (AVTX) quarterly Deferred Taxes came in at $12000.0 in Q1 2026, up 50.0% YoY from $8000.0 in Q1 2025, and down 90.84% on a QoQ basis from $131000.0 in Q4 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of Deferred Taxes data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Deferred Taxes rose 50.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169000.0 (up 46.96% YoY) and the FY2025 annual result came in at $165000.0, up 44.74% from the prior year.
- Deferred Taxes retreated to $12000.0 in Q1 2026, from $131000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $131000.0 in Q4 2025 to a low of -$14000.0 in Q3 2024.
- A 5-year average of $19588.2 and a median of $8000.0 in 2022 frame the typical range for Deferred Taxes.
- The widest YoY moves for Deferred Taxes: up 1366.67% in 2024, down 275.0% in 2024.
- Tracing AVTX's Deferred Taxes over 5 years: stood at $8000.0 in 2022, then tumbled by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then rose by 14.91% to $131000.0 in 2025, then tumbled by 90.84% to $12000.0 in 2026.
- The last three Deferred Taxes figures came in at $12000.0 (Q1 2026), $131000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | 17,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 9,000.00 |